CTNM Contineum Therapeutics, Inc.
Contineum Therapeutics, Inc. (CTNM) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $462.3K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Stengone Carmine N. | CEO and President | Sell 10b5-1 | 2,500 | $16.46 | $41.1K | 17,217 −12.7% of holding | |
| Stengone Carmine N. | CEO and President | Sell 10b5-1 | 2,500 | $16.01 | $40.0K | 17,217 −12.7% of holding | |
| Lorrain Daniel S. | Chief Scientific Officer | Sell 10b5-1 | 25 | $16.00 | $400 | 135,202 −0% of holding | |
| Stengone Carmine N. | CEO and President | Sell 10b5-1 | 2,500 | $16.00 | $40.0K | 17,217 −12.7% of holding | |
| Lorrain Daniel S. | Chief Scientific Officer | Sell 10b5-1 | 1,015 | $16.00 | $16.2K | 135,202 −0.7% of holding | |
| Lorrain Daniel S. 2 fills | Chief Scientific Officer | Sell 10b5-1 | 8,353 | $15.84 | $132.3K | 137,703 −5.7% of holding | |
| Lorrain Daniel S. | Chief Scientific Officer | Sell 10b5-1 | 28,826 | $16.04 | $462.3K | 139,372 −17.1% of holding | |
| Watkins Tim | CMO & Head of Development | Sell 10b5-1 | 10,833 | $16.02 | $173.6K | 8,961 −54.7% of holding | |
| Stengone Carmine N. | CEO and President | Sell 10b5-1 | 10,000 | $16.01 | $160.1K | 17,217 −36.7% of holding | |
| Lorrain Daniel S. | Chief Scientific Officer | Sell 10b5-1 | 4,170 | $13.16 | $54.9K | 139,372 −2.9% of holding | |
| Lorrain Daniel S. 2 fills | Chief Scientific Officer | Sell 10b5-1 | 4,170 | $13.12 | $54.7K | 143,842 −2.8% of holding | |
| Lorrain Daniel S. | Chief Scientific Officer | Sell 10b5-1 | 4,170 | $13.43 | $56.0K | 147,712 −2.7% of holding | |
| Lorrain Daniel S. | Chief Scientific Officer | Sell 10b5-1 | 4,170 | $15.01 | $62.6K | 151,882 −2.7% of holding | |
| Watkins Tim | CMO & Head of Development | Sell 10b5-1 | 3,611 | $15.02 | $54.2K | None left | |
| Lorrain Daniel S. | Chief Scientific Officer | Sell 10b5-1 | 3,824 | $16.01 | $61.2K | 156,052 −2.4% of holding | |
| Stengone Carmine N. | CEO and President | Sell 10b5-1 | 2,700 | $16.02 | $43.2K | 14,954 −15.3% of holding | |
| Stengone Carmine N. | CEO and President | Sell 10b5-1 | 4,400 | $16.02 | $70.5K | 14,954 −22.7% of holding | |
| Lorrain Daniel S. | Chief Scientific Officer | Sell 10b5-1 | 4,300 | $16.03 | $68.9K | 156,052 −2.7% of holding | |
| Lorrain Daniel S. | Chief Scientific Officer | Sell 10b5-1 | 100 | $16.00 | $1.6K | 156,052 −0.1% of holding | |
| Stengone Carmine N. | CEO and President | Sell 10b5-1 | 400 | $16.00 | $6.4K | 14,954 −2.6% of holding | |
| Lorrain Daniel S. | Chief Scientific Officer | Sell 10b5-1 | 400 | $16.00 | $6.4K | 156,052 −0.3% of holding | |
| Lorrain Daniel S. 2 fills | Chief Scientific Officer | Sell 10b5-1 | 4,170 | $14.94 | $62.3K | 157,222 −2.6% of holding | |
| Watkins Tim 2 fills | CMO & Head of Development | Sell 10b5-1 | 3,611 | $14.18 | $51.2K | 811 −81.7% of holding | |
| Lorrain Daniel S. 2 fills | Chief Scientific Officer | Sell 10b5-1 | 4,170 | $10.44 | $43.5K | 160,722 −2.5% of holding | |
| Watkins Tim | CMO & Head of Development | Sell 10b5-1 | 3,611 | $12.06 | $43.6K | None left | |
| Lorrain Daniel S. | Chief Scientific Officer | Sell 10b5-1 | 4,170 | $12.23 | $51.0K | 164,392 −2.5% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.